| Literature DB >> 25953808 |
Mark A Webber1, Rebekah N Whitehead2, Manuella Mount2, Nick J Loman3, Mark J Pallen4, Laura J V Piddock2.
Abstract
OBJECTIVES: Biocides are widely used to prevent infection. We aimed to determine whether exposure of Salmonella to various biocides could act as a driver of antibiotic resistance.Entities:
Keywords: MDR; disinfectant; efflux
Mesh:
Substances:
Year: 2015 PMID: 25953808 PMCID: PMC4500774 DOI: 10.1093/jac/dkv109
Source DB: PubMed Journal: J Antimicrob Chemother ISSN: 0305-7453 Impact factor: 5.790
Figure 1.Comparison of mutant selection between sub-culture and biocide. (a) Number of mutants identified at each sub-culture. (b) Number of mutants identified after exposure to each biocide. (c) Identification of mutants per sub-culture by biocide.
Antimicrobial susceptibility of representative mutants selected after biocide exposure
| Selective biocide | Sub-culturea | MIC (mg/L)b | ||||||
|---|---|---|---|---|---|---|---|---|
| NAL | CIP | CHL | TET | KAN | TRI | |||
| Strain | ||||||||
| SL1344 | none | 8 | 2 | <0.015 | 1 | 0.5 | 4 | 0.06 |
| AQ1 | AQAS | 5 | 0.015 | 2 | 0.5 | 8 | 0.015 | |
| AQ2 | AQAS | 6 | 0.06 | 4 | ||||
| AQ4 | AQAS | 8 | 0.06 | 4 | 0.25 | |||
| AQ5 | AQAS | 8 | 0.03 | 4 | ||||
| SK1 | Superkill | 2 | 0.12 | 2 | ||||
| SK3 | Superkill | 5 | 0.12 | 4 | ||||
| SK4 | Superkill | 6 | 0.06 | 4 | ||||
| SK7 | Superkill | 7 | 4 | <0.015 | 4 | 1 | 4 | |
| T2 | Trigene | 2 | 1 | 0.5 | 4 | |||
| T3 | Trigene | 3 | 1 | 0.5 | 4 | |||
| T6 | Trigene | 4 | 1 | 0.5 | 4 | |||
| T9 | Trigene | 5 | 1 | 0.5 | 4 | |||
| V2 | Virkon | 2 | 4 | 2 | 4 | 0.25 | ||
| V4 | Virkon | 4 | 8 | <0.015 | 4 | 2 | 4 | |
| V6 | Virkon | 6 | 4 | 2 | 4 | 0.25 | ||
| V8 | Virkon | 8 | <0.015 | 2 | 2 | |||
| Site-directed mutants and complements | ||||||||
| SL1344- | NA | NA | 0.015 | 2 | 0.5 | 8 | 0.015 | |
| SL1344- | NA | NA | 2 | <0.015 | 1 | 0.5 | 4 | 0.06 |
| T2-pBAD- | NA | NA | 1 | 0.5 | 4 | |||
| AQ1-pBAD- | NA | NA | 2 | <0.015 | 1 | 0.5 | 4 | 0.06 |
| AQ2-pBAD- | NA | NA | 0.06 | 4 | ||||
NAL, nalidixic acid; CIP, ciprofloxacin; CHL, chloramphenicol; TET, tetracycline; KAN, kanamycin; TRI, triclosan; NA, not applicable.
aNumber of biocide exposures after which each strain was recovered.
bValues in bold indicate MICs ≥8-fold higher compared with SL1344.
Mutations identified in the genome-sequenced mutants
| Strain | Gene | Start positiona | End positiona | Reference | Consensus | Type of mutation | Consequence | Fitnessb |
|---|---|---|---|---|---|---|---|---|
| AQ1 | 1 152 569 | 1 152 569 | T | G | SNP | F-V | — | |
| 3 604 893 | 3 604 893 | T | A | SNP | N294Y | |||
| AQ2 | 638 142 | 638 142 | C | T | SNP | G-D | — | |
| 3 604 893 | 3 604 893 | T | A | SNP | N294Y | |||
| AQ4 | 637 844 | 637 845 | GT | — | deletion | loss of function | — | |
| 3 604 893 | 3 604 893 | T | A | SNP | N294Y | |||
| AQ5 | 637 844 | 637 845 | GT | — | deletion | loss of function | — | |
| 3 604 893 | 3 604 893 | T | A | SNP | N294Y | |||
| SK1 | 637 708 | 637 719 | GATCGCGCGCGG | — | deletion | loss of function | — | |
| SK3 | 637 708 | 637 719 | GATCGCGCGCGG | — | deletion | loss of function | — | |
| SK4 | 637 708 | 637 719 | GATCGCGCGCGG | — | deletion | loss of function | — | |
| T2 | 1 749 266 | 1 749 266 | G | T | SNP | G93V | 0.94 | |
| 2 373 804 | 2 373 804 | T | C | SNP | D87G | |||
| 4 483 329 | 4 483 329 | — | GC | insertion | loss of function | |||
| T3 | 1 749 266 | 1 749 266 | G | T | SNP | G93V | 0.94 | |
| 2 373 804 | 2 373 804 | T | C | SNP | D87G | |||
| 4 483 329 | 4 483 329 | — | GC | insertion | loss of function | |||
| T6 | 1 749 266 | 1 749 266 | G | T | SNP | G93V | 0.94 | |
| 2 373 804 | 2 373 804 | T | C | SNP | D87G | |||
| 4 483 329 | 4 483 329 | — | GC | insertion | loss of function | |||
| T9 | 1 749 266 | 1 749 266 | G | T | SNP | G93V | 0.94 | |
| 2 373 804 | 2 373 804 | T | C | SNP | D87G | |||
| 4 483 329 | 4 483 329 | — | GC | insertion | loss of function | |||
| V2 | 2 373 804 | 2 373 804 | T | C | SNP | D87G | — | |
| V4 | 1 749 266 | 1 749 266 | G | T | SNP | G93V | — | |
| 3 874 433 | 3 874 433 | A | — | deletion | loss of function | |||
| V6 | 2 373 803 | 2 373 803 | C | A | SNP | D87G | — | |
| V8 | 1 749 266 | 1 749 266 | G | T | SNP | G93V | — |
aStart and end positions relevant to SL1344 genome.
bCalculated in competition assays; ‘—’ indicates no significant difference compared with SL1344.
Figure 2.Growth kinetics of selected mutant strains in comparison with SL1344. Growth kinetics were determined by measuring the OD at 600 nm of cultures every 10 min over 16 h; data shown are the averages of eight replicate cultures for each strain.